FIGHT-202: pemigatinib for FGFR2 altered CCA

Final results from FIGHT-202: pemigatinib for patients with FGFR-mutated advanced cholangiocarcinomaПодробнее

The rapid growth of FGFR2 inhibitors: pemigatinib in FIGHT-202Подробнее

FGFR2 Inhibitors in Advanced CholangiocarcinomaПодробнее

Advances in FGFR inhibition for hepatobiliary cancerПодробнее

Efficacy of second-line chemotherapy in advanced CCA with FGFR2 fusionsПодробнее

Impact of prior systemic therapy on PFS patients enrolled in FIGHT-202Подробнее

FIGHT-202 data: pemigatinib for previously treated locally advanced/metastatic cholangiocarcinomaПодробнее

FIGHT-202: pemigatinib in CCAПодробнее

Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2Подробнее

FGFR MutationsПодробнее

AC22 - Explore Signaling Pathways and Combination Therapy in FGFR2-activated CholangiocarcinomaПодробнее

FGFR Inhibition in Advanced CCAПодробнее

Second-Line Systemic Therapy in HCCПодробнее

FGFR Inhibitors in Development for CCAПодробнее

PROOF 301: infigratinib in advanced CCAПодробнее

Dr. Roychowdhury on FGFR Inhibitor Infigratinib in CholangiocarcinomaПодробнее

FGFR Inhibitors for CCA & Bladder CancerПодробнее

FDA Approved Pemigatinib new drug for cholangiocarcinoma, $18, 448 For 14 Days, But I'm 2 Die 2Подробнее

Novel advances in cholangiocarcinomaПодробнее